The overall goal of this program is to leverage cutting edge technology in genomics to improve diagnostic methods and treatment options available to individuals suffering from leukemia. The team of researcher-clinicians led by Drs. Guy Sauvageau and Josée Hébert from the Institut de Recherche en Immunologie et Cancérologie (IRIC) and Maisonneuve Rosemont Hospital, have developed a novel chemogenomic platform to identify small molecules, the response to which could be predictive of treatment benefit. These molecules could ultimately serve as both a prognostic tool for treatment, as well as in the identification of potential novel therapeutic targets (and hits) for AML. In addition, this program will investigate new methods of identification for minimal residual disease (MRD) in patients, the detection of which could prove useful to better treat this aggressive form of the disease.